<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060385</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-20991</org_study_id>
    <secondary_id>EORTC-20991</secondary_id>
    <nct_id>NCT00060385</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells. It is&#xD;
      not yet known which combination chemotherapy regimen is more effective in treating&#xD;
      non-Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: Randomized phase II/III trial to compare the effectiveness of combination&#xD;
      chemotherapy with or without etoposide in treating older patients who have non-Hodgkin's&#xD;
      lymphoma that has not been previously treated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the complete response rates in older patients with diffuse large B-cell or&#xD;
           peripheral T-cell non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin,&#xD;
           vincristine, and prednisone (CHOP) with vs without etoposide.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the time to treatment failure in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the freedom from progression in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the toxicity of CHOP plus etoposide in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      cellular type (B-cell vs T-cell), initial stage of disease (I and II vs III and IV), WHO&#xD;
      performance status (0-1 vs 2), and lactic dehydrogenase level (LDH) (normal vs abnormal).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (CHOP chemotherapy): Patients receive cyclophosphamide IV, doxorubicin IV, and&#xD;
           vincristine IV on day 1. Patients also receive oral prednisone on days 1-5. Treatment&#xD;
           repeats every 21 days for 3 courses in the absence of unacceptable toxicity. Patients&#xD;
           then undergo disease evaluation.&#xD;
&#xD;
      Patients with disease progression or no change in disease are removed from study. Patients&#xD;
      with responsive stage I or II disease receive 1 additional course if they demonstrate all 3&#xD;
      of the following conditions (at baseline): no LDH elevation, WHO performance status of 0-1,&#xD;
      and greatest single diameter of any tumor site less than 5 cm. Patients with responsive stage&#xD;
      I or II disease receive 3 additional courses if they demonstrate 1 or more of the following&#xD;
      conditions (at baseline): LDH elevation, WHO performance status 2, and/or greatest single&#xD;
      diameter of any tumor site at least 5 cm. Patients with responsive stage III or IV disease&#xD;
      receive 3 additional courses.&#xD;
&#xD;
      After the completion of chemotherapy, patients with responsive stage I or II disease undergo&#xD;
      involved field radiotherapy once daily 5 days a week for 3.5-4 weeks. Patients with initial&#xD;
      bulky stage III or IV disease may also undergo radiotherapy.&#xD;
&#xD;
        -  Arm II (CHOP chemotherapy and etoposide): Patients receive CHOP chemotherapy as in arm I&#xD;
           plus oral etoposide 2 or 3 times daily on days 1-10. Treatment repeats every 21 days for&#xD;
           3 courses in the absence of unacceptable toxicity. Patients receive additional courses&#xD;
           as in arm I.&#xD;
&#xD;
      After the completion of chemotherapy, patients with responsive stage I or II disease or&#xD;
      initial bulky stage III or IV disease undergo radiotherapy as in arm I.&#xD;
&#xD;
      Quality of life is assessed at baseline, after course 3, at the end of chemotherapy, every 6&#xD;
      months for 3 years, and then annually thereafter.&#xD;
&#xD;
      Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 686 patients (126 for phase II and 560 for phase III) will be&#xD;
      accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>March 2003</start_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">3</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPOCH regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of diffuse large B-cell* or peripheral T-cell non-Hodgkin's lymphoma by&#xD;
             REAL/WHO classification, including the following:&#xD;
&#xD;
               -  All morphological and clinical variants&#xD;
&#xD;
               -  All Ann Arbor stages NOTE: *Presence of a small cell, indolent lymphoma component&#xD;
                  in the bone marrow biopsy is allowed&#xD;
&#xD;
          -  No Burkitt-like lymphoma&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  No cerebral or meningeal involvement&#xD;
&#xD;
          -  At least 1 measurable target lesion at least 1.1 cm by the Cheson criteria&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  70 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3 (unless related to bone marrow infiltration)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.8 mg/dL*&#xD;
&#xD;
          -  AST or ALT less than 2.5 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  Alkaline phosphatase less than 4 times ULN* NOTE: *Values above these thresholds are&#xD;
             allowed only if related to non-Hodgkin's lymphoma&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of concurrent severe disease that would preclude study treatment&#xD;
&#xD;
          -  No other prior or concurrent malignancy except adequately treated basal cell skin&#xD;
             cancer, curatively treated carcinoma in situ of the cervix, or other curatively&#xD;
             treated solid malignancy with no evidence of disease for at least 5 years prior to&#xD;
             study entry&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance and follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent participation in another investigational drug study&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Soubeyran, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

